STAT3 and cancer: In addition, the downregulation of IL6-JAK-STAT3 signaling in the high-risk samples was inconsistent with the enrichment of M2-type macrophages, which indicates that non-classical activation of STAT3, such as through the EGFR or inflammasome pathway, is the dominant driver of cancer.